A comprehensive view of Skin Disorders/Dermatology. This page highlights a small sample of our full coverage.
For real-time access, please log in to your R&D/Patents Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

University of Bradford to create project to fund initiatives that research skin microbiome as part of UK government's Skin Microbiome in Healthy Aging scheme; project to investigate research areas including women's health, effect of menopause on skin

Moisturizing lotions, creams, gels, ointments have same effectiveness treating eczema in children six months to 12 years-old; stinging reported in 9% of cases with ointments, 17% with creams, 19% with gels, 20% with lotions: study

Regeneron and Sanofi’s injectable anti-inflammatory drug Dupixent dupilumab cleared in US to treat children six months to five years old with atopic dermatitis or eczema; drug had previously been approved for children aged six years and older

FDA accepts priority review of Regeneron and Sanofi’s sBLA for Dupixent Medical dupilumab injectable to treat adults with prurigo nodularis; if approved, Dupixent would be only drug to treat prurigo nodularis in US

Global dermatological drug market projected to reach US$47.9B by 2027, with CAGR growth of 11.22% from 2020 to 2027 due to rapid growth of people with skin problems; acne affects up to 50 million people in US each year, rosacea affects 16 million in US

Ask us about our R&D/Patents market view

Trending Chart

Interactive chart with headline count